Brad Bolzon

Brad Bolzon, Ph.D., is Chairman and Managing Director of Versant. He combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale), Speedel (sale), Quanticel (sale), Novira (sale), Flexion (2014 IPO), Crispr (2016 IPO), BioTie (sale), Jecure (sale), Inception (multiple sales), BlueRock (sale) and Black Diamond (2020 IPO), Northern Biologics (sale), and he continues to manage several other promising investments.